Skip to main content
MESO logo

Mesoblast Limited

MESONASDAQHealthcareBiotechnology

$12.39Today:- (-)1Y −26.61%

As of Oct 26, 2026 close

Market cap
$1.60B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$11.89$21.50
Volume (live)
-
Avg. volume (3M)
260.29K

Mesoblast (MESO) Income Statement

Mesoblast reported revenue of $120.25M in fiscal 2026 (fiscal year ended Jun 30, 2026), up 599.2% from $17.20M a year earlier. Mesoblast posted a net loss of $57.50M, compared with a net loss of $102.14M a year earlier. Gross margin was 86.1% and operating margin -42.6%.

Mesoblast Income Statement Analysis

Values in billions USD

Scroll to see more
Mesoblast Limited income statement - Annual data in billions USD
BreakdownFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
Revenue & Gross Profit
Revenue0.120.020.010.010.010.010.030.020.020.00
Cost of Revenue0.020.020.040.050.060.090.080.080.010.01
Gross Profit0.100.01-0.040.01-0.050.01-0.05-0.060.01-0.01
Operating Expenses
Research & Development0.100.020.030.050.030.050.060.060.070.06
Selling, General & Administrative0.060.040.020.030.060.060.050.040.030.04
Operating Expenses0.150.090.050.070.090.100.110.100.090.09
Operating Income-0.05-0.08-0.08-0.06-0.08-0.09-0.07-0.08-0.08-0.09
Other Income/Expense
Interest Income0.000.000.000.000.000.000.000.000.000.00
Interest Expense0.02-0.020.02-0.020.02-0.020.010.010.000.00
Other Income/Expense0.01-0.020.00-0.020.01-0.01-0.01-0.020.010.00
Income
Income Before Tax-0.06-0.10-0.09-0.08-0.09-0.10-0.09-0.10-0.07-0.09
Income Tax Expense0.000.000.000.000.000.00-0.01-0.01-0.03-0.01
Net Income-0.06-0.10-0.09-0.08-0.09-0.10-0.08-0.09-0.04-0.08
Net Income - Continuous Operations-0.06-0.10-0.09-0.08-0.09-0.10-0.08-0.09-0.04-0.08
Net Income - Discontinued Operations----------
EBITDA-0.04-0.06-0.06-0.07-0.07-0.08-0.07-0.08-0.07-0.09
EBIT-0.04-0.06-0.06-0.07-0.07-0.09----
Depreciation & Amortization0.010.000.000.000.000.000.000.000.000.00
Earnings Per Share
Basic EPS---1.00--134.00-2.00-1.00-2.00-1.00-1.00
Diluted EPS--1.00-1.00-1.00-134.00-2.00-1.00-2.00-1.00-1.00
Basic Shares Outstanding1.291.210.100.780.070.060.050.050.050.05
Diluted Shares Outstanding1.291.210.100.780.070.060.050.050.050.05

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Mesoblast Financial Statements

What was Mesoblast's revenue in fiscal 2026?

Mesoblast reported revenue of $120.25M in fiscal 2026 (fiscal year ended Jun 30, 2026). That was up 599.2% from $17.20M a year earlier.

Is Mesoblast profitable?

No. Mesoblast reported a net loss of $57.50M in fiscal 2026. In fiscal 2025 it lost $102.14M.

What is Mesoblast's operating margin?

Mesoblast's operating income was −$51.25M on revenue of $120.25M in fiscal 2026, an operating margin of -42.6%, compared with -458.4% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition